october 25 2005 1 ims health incorporated or its affiliates all rights reserved what is pharma looking for in an early stage opportunity how can biotechs stand out from the crowd bionetwork 2 we want to look at this different perspectives state of s portfolio and pipeline why biotech it a do stakeholders as well 3 already average 19 big sales are licensed drugs percentage products top 20 global corporations 0 40 60 80 100 p f iz er gl axos m ith k line jo h ns o n & john me r c co nov ti t ze e ca av tis roch br i l myers sqb wyeth
